T cell biomarkers come to the fore in cancer immunotherapy

Lozan Sheriff; Alastair Copland; David Bending

doi:10.1016/j.xcrm.2023.100989

T cell biomarkers come to the fore in cancer immunotherapy

Lozan Sheriff, Alastair Copland, David Bending^*

^*Corresponding author for this work

Immunology and Immunotherapy

Research output: Contribution to journal › Comment/debate

Abstract

A comprehensive study by van der Sluis et al.¹ demonstrates immunotherapeutic targeting of OX40 and PD-L1 results in enhanced tumor clearance, which is linked to the dynamic emergence of distinct subsets of CD8⁺ T cells.

Original language	English
Article number	100989
Number of pages	2
Journal	Cell Reports Medicine
Volume	4
Issue number	4
Early online date	30 Mar 2023
DOIs	https://doi.org/10.1016/j.xcrm.2023.100989
Publication status	Published - 18 Apr 2023

Bibliographical note

Keywords

Humans
CD8-Positive T-Lymphocytes/pathology
Immunotherapy/adverse effects
Neoplasms/therapy
Biomarkers

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.xcrm.2023.100989Licence: Creative Commons: Attribution (CC BY)

Regulation of TCR signalling dynamics during T follicular helper cell responses
Bending, D.
LISTER INSTITUTE OF PREVENTATIVE MEDICINE
1/10/22 → 30/09/27
Project: Research
Negative feedback control of T cells in tolerance and cancer - from pathways to biomarkers
Bending, D.
Medical Research Council
1/02/21 → 31/01/26
Project: Research Councils

Cite this

@article{e61c6e8e76c04e25a0bd6dbc4a68bb99,

title = "T cell biomarkers come to the fore in cancer immunotherapy",

abstract = "A comprehensive study by van der Sluis et al.1 demonstrates immunotherapeutic targeting of OX40 and PD-L1 results in enhanced tumor clearance, which is linked to the dynamic emergence of distinct subsets of CD8+ T cells. ",

keywords = "Humans, CD8-Positive T-Lymphocytes/pathology, Immunotherapy/adverse effects, Neoplasms/therapy, Biomarkers",

author = "Lozan Sheriff and Alastair Copland and David Bending",

note = "Copyright {\textcopyright} 2023 The Author(s). Published by Elsevier Inc.",

year = "2023",

month = apr,

day = "18",

doi = "10.1016/j.xcrm.2023.100989",

language = "English",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - T cell biomarkers come to the fore in cancer immunotherapy

AU - Sheriff, Lozan

AU - Copland, Alastair

AU - Bending, David

PY - 2023/4/18

Y1 - 2023/4/18

N2 - A comprehensive study by van der Sluis et al.1 demonstrates immunotherapeutic targeting of OX40 and PD-L1 results in enhanced tumor clearance, which is linked to the dynamic emergence of distinct subsets of CD8+ T cells.

AB - A comprehensive study by van der Sluis et al.1 demonstrates immunotherapeutic targeting of OX40 and PD-L1 results in enhanced tumor clearance, which is linked to the dynamic emergence of distinct subsets of CD8+ T cells.

KW - Humans

KW - CD8-Positive T-Lymphocytes/pathology

KW - Immunotherapy/adverse effects

KW - Neoplasms/therapy

KW - Biomarkers

U2 - 10.1016/j.xcrm.2023.100989

DO - 10.1016/j.xcrm.2023.100989

M3 - Comment/debate

C2 - 37001529

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 4

M1 - 100989

ER -

T cell biomarkers come to the fore in cancer immunotherapy

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Projects

Regulation of TCR signalling dynamics during T follicular helper cell responses

Negative feedback control of T cells in tolerance and cancer - from pathways to biomarkers

Cite this